File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children

TitleEffect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children
Authors
Issue Date1991
Citation
Quarterly Journal Of Medicine, 1991, v. 78 n. 286, p. 155-163 How to Cite?
AbstractNinety Chinese hepatitis B surface antigen (HBsAg) carrier children, aged 2-17 years, positive for hepatitis B e antigen (HBeAg) and hepatitis B virus DNA on at least three occasions in 6 months, were randomized into 3 groups. Thirty children received syrup vitamin B complex as control, 29 received 6 weeks of placebo syrup followed by 16 weeks of recombinant α(2b)-interferon [intron A (rIFN(2b))], 5 x 10 6 u/m 2 subcutaneously thrice weekly; and 31 received 6 weeks of syrup prednisone (0.6 mg/kg tailed to 0.2 mg/kg) followed by 16 weeks of recombinant α(2b)-interferon as above. The placebo/prednisone syrup was given on a double-blind basis. At 24 months of follow-up, persistent loss of hepatitis B virus DNA occurred in none of the children in the control group, in one child receiving recombinant α(2b)-interferon alone, who also seroconverted to anti-HBe and anti-HBs and in five children receiving interferon with steroid priming (p = 0.0571 compared with controls), with four seroconverting to anti-HBe and one also seroconverting to anti-HBs. A rise of transaminases to above twice the upper limit of normal levels during the first 7 months of follow-up occurred in one subject in the control group, four in the group receiving α(2b)-interferon alone and nine in the group receiving recombinant α(2b)-interferon with steroid priming (p = 0.0144 compared with controls). Side effects of the steroid were negligible; those of recombinant α(2b)-interferon were transient and acceptable. We conclude that 6 weeks of prednisone followed by 16 weeks of recombinant α(2b)-interferon is of use in inducing persistent loss of hepatitis B virus DNA (16.1 per cent) and e-seroconversion (12.9 per cent) in a proportion of Chinese HBsAg carrier children: the prednisone probably enhances the immunomodulatory effect of recombinant α(2b)-interferon.
Persistent Identifierhttp://hdl.handle.net/10722/161886
ISSN
1998 Impact Factor: 2.244
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_US
dc.contributor.authorLin, HJen_US
dc.contributor.authorLau, JYNen_US
dc.contributor.authorLok Wu, ASFPCen_US
dc.contributor.authorChung, HTen_US
dc.contributor.authorWong, LSKen_US
dc.contributor.authorLeung, MPen_US
dc.contributor.authorYeung, CYen_US
dc.date.accessioned2012-09-05T05:15:49Z-
dc.date.available2012-09-05T05:15:49Z-
dc.date.issued1991en_US
dc.identifier.citationQuarterly Journal Of Medicine, 1991, v. 78 n. 286, p. 155-163en_US
dc.identifier.issn0033-5622en_US
dc.identifier.urihttp://hdl.handle.net/10722/161886-
dc.description.abstractNinety Chinese hepatitis B surface antigen (HBsAg) carrier children, aged 2-17 years, positive for hepatitis B e antigen (HBeAg) and hepatitis B virus DNA on at least three occasions in 6 months, were randomized into 3 groups. Thirty children received syrup vitamin B complex as control, 29 received 6 weeks of placebo syrup followed by 16 weeks of recombinant α(2b)-interferon [intron A (rIFN(2b))], 5 x 10 6 u/m 2 subcutaneously thrice weekly; and 31 received 6 weeks of syrup prednisone (0.6 mg/kg tailed to 0.2 mg/kg) followed by 16 weeks of recombinant α(2b)-interferon as above. The placebo/prednisone syrup was given on a double-blind basis. At 24 months of follow-up, persistent loss of hepatitis B virus DNA occurred in none of the children in the control group, in one child receiving recombinant α(2b)-interferon alone, who also seroconverted to anti-HBe and anti-HBs and in five children receiving interferon with steroid priming (p = 0.0571 compared with controls), with four seroconverting to anti-HBe and one also seroconverting to anti-HBs. A rise of transaminases to above twice the upper limit of normal levels during the first 7 months of follow-up occurred in one subject in the control group, four in the group receiving α(2b)-interferon alone and nine in the group receiving recombinant α(2b)-interferon with steroid priming (p = 0.0144 compared with controls). Side effects of the steroid were negligible; those of recombinant α(2b)-interferon were transient and acceptable. We conclude that 6 weeks of prednisone followed by 16 weeks of recombinant α(2b)-interferon is of use in inducing persistent loss of hepatitis B virus DNA (16.1 per cent) and e-seroconversion (12.9 per cent) in a proportion of Chinese HBsAg carrier children: the prednisone probably enhances the immunomodulatory effect of recombinant α(2b)-interferon.en_US
dc.languageengen_US
dc.relation.ispartofQuarterly Journal of Medicineen_US
dc.subject.meshAdolescenten_US
dc.subject.meshCarrier State - Microbiology - Therapyen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshChinaen_US
dc.subject.meshDna, Viral - Analysisen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B - Microbiology - Therapyen_US
dc.subject.meshHepatitis B Surface Antigens - Analysisen_US
dc.subject.meshHepatitis B E Antigens - Analysisen_US
dc.subject.meshHepatitis B Virus - Isolation & Purificationen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon-Alpha - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshPrednisone - Therapeutic Useen_US
dc.subject.meshRecombinant Proteinsen_US
dc.titleEffect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier childrenen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2031078en_US
dc.identifier.scopuseid_2-s2.0-0025970995en_US
dc.identifier.volume78en_US
dc.identifier.issue286en_US
dc.identifier.spage155en_US
dc.identifier.epage163en_US
dc.identifier.isiWOS:A1991FB15600007-
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridLin, HJ=7405571292en_US
dc.identifier.scopusauthoridLau, JYN=7402446047en_US
dc.identifier.scopusauthoridLok Wu, ASFPC=35379868500en_US
dc.identifier.scopusauthoridChung, HT=7404007053en_US
dc.identifier.scopusauthoridWong, LSK=7402091922en_US
dc.identifier.scopusauthoridLeung, MP=7201944800en_US
dc.identifier.scopusauthoridYeung, CY=7201354144en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats